These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 819373)

  • 41. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa.
    Golpasha ID; Mousavi SF; Owlia P; Siadat SD; Irani S
    Bosn J Basic Med Sci; 2015 May; 15(2):15-24. PubMed ID: 26042508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effectiveness of tobramycin and immunologic preparations in experimental Pseudomonas infection].
    Minukhin VV; Tsyganenko AIa
    Antibiot Khimioter; 1989 Apr; 34(4):282-6. PubMed ID: 2502083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of immunotherapy for infections due to Pseudomonas aeruginosa.
    Fisher MW
    J Infect Dis; 1974 Nov; 130 Suppl(0):S149-51. PubMed ID: 4138585
    [No Abstract]   [Full Text] [Related]  

  • 44. Pseudomonas aeruginosa. Vaccines and immunotherapy.
    Pennington JE
    Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. II. Opsonic, agglutinative, and protective capacities of immunoglobulin G anti-Pseudomonas antibodies.
    Bjornson AB; Michael JG
    Infect Immun; 1972 May; 5(5):775-82. PubMed ID: 4629252
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice.
    Powderly WG; Pier GB; Markham RB
    J Clin Invest; 1986 Aug; 78(2):375-80. PubMed ID: 2426306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host.
    Pennington JE; Small GJ
    J Infect Dis; 1987 May; 155(5):973-8. PubMed ID: 3104484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections.
    Meynet E; Laurin D; Lenormand JL; Camara B; Toussaint B; Le Gouëllec A
    Vaccine; 2018 Mar; 36(14):1893-1900. PubMed ID: 29506924
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Production and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. IV. The effect of immunization with Pseudomonas aeruginosa vaccine on the immune status of volunteer donors].
    Titova TI; Sidorova TN; Radkevich SA; Antsiferova NG; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Aug; (8):80-4. PubMed ID: 3933225
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pseudomonas aeruginosa vaccine in cancer patients.
    Young LS; Meyer RD; Armstrong D
    Ann Intern Med; 1973 Oct; 79(4):518-27. PubMed ID: 4201225
    [No Abstract]   [Full Text] [Related]  

  • 52. Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies.
    Ann Intern Med; 1975 Jun; 82(6):819-31. PubMed ID: 806246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli.
    Finke M; Duchêne M; Eckhardt A; Domdey H; von Specht BU
    Infect Immun; 1990 Jul; 58(7):2241-4. PubMed ID: 2114360
    [TBL] [Abstract][Full Text] [Related]  

  • 54. X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas aeruginosa.
    Li Y; Wang Z; Liu X; Tang J; Peng B; Wei Y
    Sci Rep; 2016 Feb; 6():18823. PubMed ID: 26879055
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis.
    Pennington JE
    J Infect Dis; 1974 Nov; 130 Suppl(0):S159-62. PubMed ID: 4213986
    [No Abstract]   [Full Text] [Related]  

  • 56. Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa.
    Sawada S; Kawamura T; Masuho Y; Tomibe K
    J Infect Dis; 1985 Nov; 152(5):965-70. PubMed ID: 3930629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Ttitova TI; Grigor'ev NI; Antsiferova NG; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):14-8. PubMed ID: 3931392
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunization of mice and chinchillas against Pseudomonas aeruginosa.
    Lusis PI; Soltys MA
    Can J Comp Med; 1971 Jan; 35(1):60-6. PubMed ID: 4251417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experimental bacteremia due to Pseudomonas in agranulocytic animals.
    Ziegler EJ; Douglas H; Braude AI
    J Infect Dis; 1974 Nov; 130 Suppl(0):S145-8. PubMed ID: 4214311
    [No Abstract]   [Full Text] [Related]  

  • 60. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.